Cost analysis of in-centre nocturnal compared with conventional hemodialysis

Table 2 Impact of difference in medication requirement on relative costs between ICNHD and CvHD

Resource category	CvHD ¹($)	ICNHD ($)	Δ Cost ($, ICNHD – CvHD)
Medication
Anti-hypertensives	756.00	378.00	(−378.00)
ESAs	6,252.00	3751.20	(−2,500.80)
Bone mineral metabolism medications	1,080.00	540.00	(−540.00)
Reference – no difference in medication use (annual cost/patient)	15,048.28	24,585.86	+ 9,537.58
Reduced anti-HTN and bone mineral metabolism medications only (annual cost/patient)	16,884.28	25,503.86	+ 8,619.58
Reduced in all medication categories (annual cost/patient)	23,136.28	29,255.06	+6,118.78

¹annual cost of CvHD was informed from the Alberta randomized-controlled trial [11].
Assumptions:
- 50% reduction in number of anti-hypertensives required based on observational studies [13–17].
- 40% reduction in required ESA dose based on observational studies [16–18].
-50% reduction in amount of bone mineral metabolism medications required based on observational studies [13, 15, 16, 18].
ICNHD: in-centre nocturnal hemodialysis (7 hour sessions, 3x /week, 1:3 staff-to patient ratio); CvHD conventional hemodialysis (4 hour sessions, 3x /week, 1:3 staff-to-patient ratio); ESAs: erythropoiesis-stimulating agents.

ISSN: 2054-3581